Immunity and amyloid beta, total tau and neurofilament light chain: Findings from a community-based cohort study

Lana Fani; Shahzad Ahmad; M. Kamran Ikram; Mohsen Ghanbari; M. Arfan Ikram

doi:10.1002/alz.12212

Immunity and amyloid beta, total tau and neurofilament light chain: Findings from a community-based cohort study

Lana Fani, Shahzad Ahmad, M. Kamran Ikram, Mohsen Ghanbari, M. Arfan Ikram^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

9 Citations (Scopus)

11 Downloads (Pure)

Abstract

Introduction: We investigated how components of immunity relate to biomarkers of Alzheimer's disease (AD) in plasma and explored the influence of AD genetic risk factors in the population-based Rotterdam Study. Methods: In 7397 persons, we calculated the granulocyte-to-lymphocyte ratio (GLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII). In 3615 of these persons, plasma amyloid-beta (Aβ)42 and Aβ40 were measured. Next, we constructed an overall genetic risk score (GRS) based on genome-wide significant variants, both including and excluding APOE ε4. Results: All innate immunity phenotypes were related to higher Aβ, most strongly with a doubling in GLR leading to a 1.9% higher Aβ42 (95% confidence interval [95% CI] 0.4 to 3.3%) and 3.2% higher Aβ40 (95% CI 2.0 to 4.3%). Higher AD GRS including APOE ε4 was associated with higher immunity markers. Discussion: Higher levels of immunity markers were associated with higher Aβ in plasma. Participants with a higher genetic predisposition to AD had higher immunity markers, where these effects were mainly driven by APOE ε4.

Original language	English
Pages (from-to)	446-456
Number of pages	11
Journal	Alzheimer's and Dementia
Volume	17
Issue number	3
Early online date	20 Nov 2020
DOIs	https://doi.org/10.1002/alz.12212
Publication status	Published - Mar 2021

Bibliographical note

Funding Information:
This study was partly funded by ZonMw Memorabel (grant number 73305095005) and Alzheimer Nederland through the Netherlands Consortium of Dementia Cohorts (NCDC) in the context of Deltaplan Dementie. Further funding was obtained from the Netherlands CardioVascular Research Initiative, the Dutch Heart Foundation (CVON 2018‐28 Heart Brain Connection Cross‐roads), Dutch Federation of University Medical Centres, the Netherlands Organisation for Health Research and Development, and the Royal Netherlands Academy of Sciences.

Funding Information:
This work was supported by the European Union's Horizon 2020 research and innovation program (grant number 667375; “CoSTREAM”); the Erasmus Medical Center and Erasmus University Rotterdam; the Netherlands Organization for Scientific Research (NWO; grant numbers 948‐00‐010, 918‐46‐615); the Netherlands Organization for Health Research and Development (ZonMw); the Research Institute for Diseases in the Elderly (RIDE); the Ministry of Education, Culture and Science; the Ministry of Health, Welfare and Sports; the European Commission (DG XII); and the Municipality of Rotterdam.

Publisher Copyright:
© 2020 The Authors. Alzheimer's & Dementia published by Wiley Periodicals, Inc. on behalf of Alzheimer's Association

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/alz.12212Licence: CC BY-NC-ND

Immunity and amyloid beta, total tau and neurofilament light chain, Findings from a community-based cohort studyFinal published version, 943 KBLicence: CC BY-NC-ND

Cite this

@article{214ed93ff39b4254b68b7442d50366b8,

title = "Immunity and amyloid beta, total tau and neurofilament light chain: Findings from a community-based cohort study",

abstract = "Introduction: We investigated how components of immunity relate to biomarkers of Alzheimer's disease (AD) in plasma and explored the influence of AD genetic risk factors in the population-based Rotterdam Study. Methods: In 7397 persons, we calculated the granulocyte-to-lymphocyte ratio (GLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII). In 3615 of these persons, plasma amyloid-beta (Aβ)42 and Aβ40 were measured. Next, we constructed an overall genetic risk score (GRS) based on genome-wide significant variants, both including and excluding APOE ε4. Results: All innate immunity phenotypes were related to higher Aβ, most strongly with a doubling in GLR leading to a 1.9% higher Aβ42 (95% confidence interval [95% CI] 0.4 to 3.3%) and 3.2% higher Aβ40 (95% CI 2.0 to 4.3%). Higher AD GRS including APOE ε4 was associated with higher immunity markers. Discussion: Higher levels of immunity markers were associated with higher Aβ in plasma. Participants with a higher genetic predisposition to AD had higher immunity markers, where these effects were mainly driven by APOE ε4.",

author = "Lana Fani and Shahzad Ahmad and Ikram, {M. Kamran} and Mohsen Ghanbari and Ikram, {M. Arfan}",

note = "Funding Information: This study was partly funded by ZonMw Memorabel (grant number 73305095005) and Alzheimer Nederland through the Netherlands Consortium of Dementia Cohorts (NCDC) in the context of Deltaplan Dementie. Further funding was obtained from the Netherlands CardioVascular Research Initiative, the Dutch Heart Foundation (CVON 2018‐28 Heart Brain Connection Cross‐roads), Dutch Federation of University Medical Centres, the Netherlands Organisation for Health Research and Development, and the Royal Netherlands Academy of Sciences. Funding Information: This work was supported by the European Union's Horizon 2020 research and innovation program (grant number 667375; “CoSTREAM”); the Erasmus Medical Center and Erasmus University Rotterdam; the Netherlands Organization for Scientific Research (NWO; grant numbers 948‐00‐010, 918‐46‐615); the Netherlands Organization for Health Research and Development (ZonMw); the Research Institute for Diseases in the Elderly (RIDE); the Ministry of Education, Culture and Science; the Ministry of Health, Welfare and Sports; the European Commission (DG XII); and the Municipality of Rotterdam. Publisher Copyright: {\textcopyright} 2020 The Authors. Alzheimer's & Dementia published by Wiley Periodicals, Inc. on behalf of Alzheimer's Association",

year = "2021",

month = mar,

doi = "10.1002/alz.12212",

language = "English",

volume = "17",

pages = "446--456",

journal = "Alzheimer's and Dementia",

issn = "1552-5260",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - Immunity and amyloid beta, total tau and neurofilament light chain

T2 - Findings from a community-based cohort study

AU - Fani, Lana

AU - Ahmad, Shahzad

AU - Ikram, M. Kamran

AU - Ghanbari, Mohsen

AU - Ikram, M. Arfan

N1 - Funding Information: This study was partly funded by ZonMw Memorabel (grant number 73305095005) and Alzheimer Nederland through the Netherlands Consortium of Dementia Cohorts (NCDC) in the context of Deltaplan Dementie. Further funding was obtained from the Netherlands CardioVascular Research Initiative, the Dutch Heart Foundation (CVON 2018‐28 Heart Brain Connection Cross‐roads), Dutch Federation of University Medical Centres, the Netherlands Organisation for Health Research and Development, and the Royal Netherlands Academy of Sciences. Funding Information: This work was supported by the European Union's Horizon 2020 research and innovation program (grant number 667375; “CoSTREAM”); the Erasmus Medical Center and Erasmus University Rotterdam; the Netherlands Organization for Scientific Research (NWO; grant numbers 948‐00‐010, 918‐46‐615); the Netherlands Organization for Health Research and Development (ZonMw); the Research Institute for Diseases in the Elderly (RIDE); the Ministry of Education, Culture and Science; the Ministry of Health, Welfare and Sports; the European Commission (DG XII); and the Municipality of Rotterdam. Publisher Copyright: © 2020 The Authors. Alzheimer's & Dementia published by Wiley Periodicals, Inc. on behalf of Alzheimer's Association

PY - 2021/3

Y1 - 2021/3

N2 - Introduction: We investigated how components of immunity relate to biomarkers of Alzheimer's disease (AD) in plasma and explored the influence of AD genetic risk factors in the population-based Rotterdam Study. Methods: In 7397 persons, we calculated the granulocyte-to-lymphocyte ratio (GLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII). In 3615 of these persons, plasma amyloid-beta (Aβ)42 and Aβ40 were measured. Next, we constructed an overall genetic risk score (GRS) based on genome-wide significant variants, both including and excluding APOE ε4. Results: All innate immunity phenotypes were related to higher Aβ, most strongly with a doubling in GLR leading to a 1.9% higher Aβ42 (95% confidence interval [95% CI] 0.4 to 3.3%) and 3.2% higher Aβ40 (95% CI 2.0 to 4.3%). Higher AD GRS including APOE ε4 was associated with higher immunity markers. Discussion: Higher levels of immunity markers were associated with higher Aβ in plasma. Participants with a higher genetic predisposition to AD had higher immunity markers, where these effects were mainly driven by APOE ε4.

AB - Introduction: We investigated how components of immunity relate to biomarkers of Alzheimer's disease (AD) in plasma and explored the influence of AD genetic risk factors in the population-based Rotterdam Study. Methods: In 7397 persons, we calculated the granulocyte-to-lymphocyte ratio (GLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII). In 3615 of these persons, plasma amyloid-beta (Aβ)42 and Aβ40 were measured. Next, we constructed an overall genetic risk score (GRS) based on genome-wide significant variants, both including and excluding APOE ε4. Results: All innate immunity phenotypes were related to higher Aβ, most strongly with a doubling in GLR leading to a 1.9% higher Aβ42 (95% confidence interval [95% CI] 0.4 to 3.3%) and 3.2% higher Aβ40 (95% CI 2.0 to 4.3%). Higher AD GRS including APOE ε4 was associated with higher immunity markers. Discussion: Higher levels of immunity markers were associated with higher Aβ in plasma. Participants with a higher genetic predisposition to AD had higher immunity markers, where these effects were mainly driven by APOE ε4.

UR - http://www.scopus.com/inward/record.url?scp=85096680133&partnerID=8YFLogxK

U2 - 10.1002/alz.12212

DO - 10.1002/alz.12212

M3 - Article

C2 - 33215849

AN - SCOPUS:85096680133

VL - 17

SP - 446

EP - 456

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 3

ER -

Immunity and amyloid beta, total tau and neurofilament light chain: Findings from a community-based cohort study

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this